RA Capital Says Better Times Ahead For Healthcare, Biotech As Fund Drops 16% In H1 – ValueWalk Premium

RA Capital Says Better Times Ahead For Healthcare, Biotech As Fund Drops 16% In H1

Halfway through 2016 – one year into the deepest drawdowns in the history of the biotech sector – a major healthcare and life sciences investment fund wants to explain its performance, rated as one of the best by one study.

RA Capital, down -16.4% year to date, says the political rhetoric will subside
After starting the year down more than -21%, but since recovering to down -16.4% as of the end of June, RA Capital Healthcare Fund . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0